Weekly Top News – Psoriasis – April 22, 2019

April 22, 2019

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Health Canada approves Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis (Canada Newswire) – Apr 18, 2019 – “AbbVie…announced today that Health Canada has approved SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy….SKYRIZI received Health Canada approval based on results from four pivotal Phase 3 studies, ultIMMa-1, ultIMMa-2, IMMvent and IMMhance evaluating more than 2,000 patients with moderate to severe plaque psoriasis.”
Canadian regulatory

 

KD025  / Kadmon
KD025 US launch estimate: 2021 in plaque psoriasis (Jefferies) – Apr 19, 2019 – A subscription to Thomson ONE is required to gain full access to report 66898956; Page no: 4; REPORT TITLE: “Kadmon Holdings Inc – Q4 ’18: Pivotal study readout for KD025 in cgvhd expected at YE ’19”; AUTHOR: Amin, Biren, et al; DATE: 03/08/2019
Launch US

 

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
NICE publishes final recommendation for Ilumetri (Pharmafield) – Apr 17, 2019 – “NICE has published final recommendation for ILUMETRI (Tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis.”
NICE

 

Tremfya (guselkumab) / J&J
A brighter future for psoriasis patients in Egypt (Egypt Today) – Apr 15, 2019 – “Ministry of health approved the first biological treatment of moderate to severe plaque psoriasis patients….Tremfya is the first biologic treatment approved by the ministry of health under resolution 820, which allows the registration of FDA-approved treatments and European EMEA in a short period of up to three months, which confirms the ministry’s mission to provide advanced biological treatments that help to heal the Egyptian patient as soon as possible.”
Non-US regulatory

 

Enbrel (etanercept) / Takeda, Pfizer, Amgen
A RANDOMIZED, PHASE 3, DOUBLE-BLIND TRIAL EXAMINING METHOTREXATE AND ETANERCEPT AS MONOTHERAPY OR IN COMBINATION FOR TREATING PSORIATIC ARTHRITIS: A COMPARISON OF THE COMPOSITE MEASURES USED TO EVALUATE DISEASE ACTIVITY (EULAR 2019) – Apr 16, 2019 – Abstract #OP0111; Pres time: Jun 13, 2019; 10:50 AM – 11:00 AM; Location: Hall 8; No abstract available.
Clinical • Monotherapy • P3 data

 

Cosentyx (secukinumab) / Novartis
SECUKINUMAB IMPROVES AXIAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NSAIDS: PRIMARY ANALYSIS OF THE MAXIMISE TRIAL (EULAR 2019) – Apr 16, 2019 – Abstract #OP0235; Pres time: Jun 14, 2019; 11:00 AM – 11:10 AM; Location: Hall 7A; No abstract available.
Clinical

 

Taltz (ixekizumab) / Eli Lilly
IXEKIZUMAB IMPROVES SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS IN PATIENTS WHO HAVE HAD INADEQUATE RESPONSE TO 1 OR 2 TUMOR NECROSIS FACTOR INHIBITORS (EULAR 2019) – Apr 16, 2019 – Abstract #OP0110; Pres time: Jun 13, 2019; 10:40 AM – 10:50 AM; Location: Hall 8; No abstract available.
Clinical

 

Cosentyx (secukinumab) / Novartis
MACHINE LEARNING TOOLS IDENTIFY PATIENT CLUSTERS AND SWOLLEN AND TENDER JOINT CORRELATION PATTERNS IN A LARGE DATABASE FROM THE SECUKINUMAB PSORIATIC ARTHRITIS CLINICAL DEVELOPMENT PROGRAM (EULAR 2019) – Apr 16, 2019 – Abstract #OP0114; Pres time: Jun 13, 2019; 11:20 AM – 11:30 AM; Location: Hall 8; No abstract available.
Clinical

 

No Comments

Post a Comment

Comment
Name
Email
Website